The Food and Drug Administration yesterday released a final rule allowing states, territories and Indian tribes to establish programs to import certain FDA-approved prescription drug and biological products from Canada.

Pharmacists and wholesalers could co-sponsor the programs, which would have to demonstrate that the imported products pose no additional risk to public health and safety and would cost consumers significantly less, and may be able to establish them in the future, FDA said.

The agency also issued final guidance describing procedures for drug makers importing foreign-made prescription drug and biological products approved by the FDA. In addition, the Centers for Medicare & Medicaid Services issued guidance on the rule’s implications for the Medicaid Drug Rebate Program.

President Trump in July issued an executive order directing the agency to take actions to allow for the importation and re-importation by states, wholesalers and pharmacies of Food and Drug Administration-approved drugs from Canada.

Related News Articles

Headline
A recent analysis from the Peterson Center on Healthcare and the Kaiser Family Foundation provides an incomplete picture of U.S. spending on health care while…
Blog
A recent analysis from the Peterson Center on Healthcare and the Kaiser Family Foundation, “What drives health spending in the U.S. compared to other countries…
Headline
The House Committee on Oversight and Reform this week concluded a two-day hearing examining pricing practices for some of the nation’s costliest drugs. As…
Headline
The House Committee on Oversight and Reform today launched a two-day hearing to examine pricing practices for some of the nation’s costliest drugs.…
Headline
President Trump yesterday issued a new executive order that seeks to lower prescription drug prices. The order directs the Secretary of Health and Human…
Headline
A new study demonstrates the cost to the U.S. health care system from an anti-competitive tactic known as “product hopping,” which involves a brand name drug…